Latest Period
Q4 2025
Security Snapshot
Protara Therapeutics, Inc. - Common Stock (TARA) Institutional Ownership
CUSIP: 74365U107
13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026
Institutions Reporting
103
Shares (Excl. Options)
39,817,794
Price
$5.33
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- TARA on Nasdaq
- Shares outstanding
- 53,769,190
- Price per share
- $5.21
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 39,817,794
- Total reported value
- $212,205,829
- % of total 13F portfolios
- 0%
- Share change
- +13,615,963
- Value change
- +$73,079,091
- Number of holders
- 103
- Price from insider filings
- $5.21
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- TARA - Protara Therapeutics, Inc. - Common Stock is tracked under CUSIP 74365U107.
- 103 institutions reported positions in Q4 2025.
- 7 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 103 to 24 between Q4 2025 and Q1 2026.
- Reported value moved from $212,205,829 to $24,574,095.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 103 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 74365U107?
CUSIP 74365U107 identifies TARA - Protara Therapeutics, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 74365U107:
Significant Owners of Protara Therapeutics, Inc. - Common Stock (TARA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 10% | -9.1% | $29,564,292 | +$5,234,139 | 5,141,616 | +22% | JANUS HENDERSON GROUP PLC | 31 Dec 2025 |
| BlackRock, Inc. | 6.3% | +32% | $17,648,661 | +$5,098,459 | 3,387,459 | +41% | BlackRock, Inc. | 31 Mar 2026 |
| MILLENNIUM MANAGEMENT LLC | 5.1% | $19,314,617 | 2,759,231 | Millennium Management LLC | 25 Feb 2026 | |||
| RA CAPITAL MANAGEMENT, L.P. | 4.9% | -50% | $5,974,448 | -$4,423,642 | 1,971,765 | -43% | RA Capital Management, L.P. | 30 Jun 2025 |
| Opaleye Management Inc. | 4.7% | -12% | $7,473,600 | -$410,400 | 1,730,000 | -5.2% | Opaleye Management, Inc. | 31 Mar 2025 |
| CITADEL ADVISORS LLC | 4.7% | $7,031,811 | 1,627,734 | Kenneth Griffin | 31 Dec 2024 | |||
| Woodline Partners LP | 3.9% | $5,751,035 | 1,331,258 | Woodline Partners LP | 31 Dec 2024 |
As of 31 Dec 2025, 103 institutional investors reported holding 39,817,794 shares of Protara Therapeutics, Inc. - Common Stock (TARA). This represents 74% of the company’s total 53,769,190 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Protara Therapeutics, Inc. - Common Stock (TARA) together control 65% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 9.6% | 5,141,616 | +22% | 0.01% | $27,379,105 |
| Velan Capital Investment Management LP | 5.3% | 2,834,652 | +33% | 8.8% | $15,108,695 |
| BlackRock, Inc. | 4.5% | 2,408,868 | +8.1% | 0% | $12,839,267 |
| VANGUARD GROUP INC | 4.4% | 2,391,903 | +26% | 0% | $12,748,844 |
| Integral Health Asset Management, LLC | 4.2% | 2,250,000 | +61% | 0.61% | $11,992,500 |
| Blackstone Inc. | 3.6% | 1,909,662 | 0% | 0.04% | $10,178,498 |
| ACORN CAPITAL ADVISORS, LLC | 3.3% | 1,752,115 | 0% | 3.2% | $9,338,773 |
| Sio Capital Management, LLC | 3.2% | 1,715,394 | 1.5% | $9,143,050 | |
| Catalio Capital Management, LP | 2.7% | 1,446,254 | -3.6% | 1.4% | $7,708,534 |
| 5AM Venture Management, LLC | 2.5% | 1,369,782 | +71% | 2.3% | $7,300,938 |
| Driehaus Capital Management LLC | 2.3% | 1,259,427 | +183% | 0.05% | $6,712,746 |
| UBS Group AG | 2.3% | 1,215,537 | +44% | 0% | $6,478,812 |
| ADAR1 Capital Management, LLC | 2.1% | 1,136,799 | +3127% | 0.45% | $6,059,139 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.9% | 1,043,478 | 0.01% | $5,561,738 | |
| BAKER BROS. ADVISORS LP | 1.8% | 971,614 | +81% | 0.03% | $5,178,703 |
| CITADEL ADVISORS LLC | 1.7% | 901,541 | +79% | 0% | $4,805,214 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.5% | 817,196 | +7.7% | 0% | $4,356,728 |
| Maven Securities LTD | 1.4% | 754,626 | 0.51% | $4,022,157 | |
| MILLENNIUM MANAGEMENT LLC | 1.4% | 753,302 | +9.5% | 0% | $4,015,100 |
| SPHERA FUNDS MANAGEMENT LTD. | 1.2% | 650,000 | 0.72% | $3,464,500 | |
| MARSHALL WACE, LLP | 1.1% | 584,528 | +105% | 0% | $3,115,534 |
| STATE STREET CORP | 1.1% | 570,878 | +63% | 0% | $3,042,780 |
| BANK OF AMERICA CORP /DE/ | 0.92% | 495,904 | +175% | 0% | $2,643,169 |
| BURKEHILL GLOBAL MANAGEMENT, LP | 0.84% | 450,000 | 0.16% | $2,398,500 | |
| SUPERSTRING CAPITAL MANAGEMENT LP | 0.67% | 360,000 | 0% | 1% | $1,918,800 |
Institutional Holders of Protara Therapeutics, Inc. - Common Stock (TARA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 4,716,972 | $24,574,095 | +$12,498,613 | $5.21 | 24 |
| 2025 Q4 | 39,817,794 | $212,205,829 | +$73,079,091 | $5.33 | 103 |
| 2025 Q3 | 26,208,473 | $113,965,432 | -$10,353,742 | $4.35 | 79 |
| 2025 Q2 | 29,714,732 | $90,054,436 | +$447,680 | $3.03 | 76 |
| 2025 Q1 | 28,759,849 | $123,767,729 | -$8,349,026 | $4.26 | 59 |
| 2024 Q4 | 29,670,168 | $156,599,526 | +$91,818,405 | $5.28 | 60 |
| 2024 Q3 | 10,445,706 | $19,115,471 | +$384,364 | $1.83 | 33 |
| 2024 Q2 | 10,449,817 | $22,236,374 | +$12,029,265 | $2.08 | 38 |
| 2024 Q1 | 4,570,660 | $18,342,843 | +$911,041 | $4.01 | 34 |
| 2023 Q4 | 4,357,920 | $8,168,237 | -$1,261,027 | $1.88 | 30 |
| 2023 Q3 | 5,117,943 | $8,547,441 | -$31,849 | $1.67 | 31 |
| 2023 Q2 | 5,136,537 | $12,262,078 | -$1,134,644 | $2.39 | 28 |
| 2023 Q1 | 5,503,158 | $16,886,987 | +$77,617 | $3.13 | 28 |
| 2022 Q4 | 5,478,113 | $14,679,319 | -$481,288 | $2.68 | 29 |
| 2022 Q3 | 5,656,228 | $16,718,296 | -$789,370 | $2.96 | 26 |
| 2022 Q2 | 5,927,042 | $18,391,293 | -$2,063,463 | $2.93 | 31 |
| 2022 Q1 | 6,495,468 | $33,192,511 | -$1,990,162 | $5.11 | 34 |
| 2021 Q4 | 6,872,165 | $46,492,675 | +$3,840,591 | $6.75 | 36 |
| 2021 Q3 | 6,311,961 | $43,679,692 | -$8,598,514 | $6.92 | 36 |
| 2021 Q2 | 7,110,843 | $69,259,000 | -$22,850,218 | $9.74 | 38 |
| 2021 Q1 | 8,528,460 | $134,015,000 | -$11,645,346 | $15.74 | 49 |
| 2020 Q4 | 8,775,745 | $212,476,065 | -$5,829,365 | $24.21 | 48 |
| 2020 Q3 | 9,281,283 | $156,208,097 | +$91,825,921 | $16.83 | 44 |
| 2020 Q2 | 3,696,566 | $108,380,809 | +$108,380,809 | $29.32 | 31 |